Gerald Commissiong

Jumpkicks, Inc. provides online retailing services. The company also provides content of interest to martial artists and selling products, such as uniforms, t-shirts, protective equipment, mats and other equipment and accessories. The company was founded on August 3, 2007 and is headquartered in Henderson, NV.

Part of Gemini Strategies LLC, Inc., Cutanogen Corp. is a company that develops artificial skin products used to treat patients with severe burns. The company is based in Cincinnati, OH. The CEO of the company is Gerald E. Commissiong. Cutanogen was acquired by Amarantus Bioscience Holdings, Inc. from Lonza Group AG on July 15, 2015 for $9 million.

Provista Diagnostics, Inc. operates as a diagnostic company. It focuses on the development and commercialization of proprietary blood based diagnostic, prognostic, and monitoring tests in women's cancer. Its products include videssa breast, ovarian, endometrial, and HPV associated. The company is headquartered in Alpharetta, GA.

Elto Pharma, Inc. develops Eltoprazine, an oral small molecule 5HT1A/1B partial agonist in clinical development for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID), aggression in Alzheimer's disease and adult attention deficit hyperactivity disorder (adult ADHD).The company was founded on April 12, 2017 and is headquartered in Nevada, the United States of America.

OS Therapies, Inc. operates as a clinical stage biopharmaceutical company. It engages in identification, development, and commercialization of treatments for Osteosarcoma and other related diseases. The company was founded by Paul A. Romness on April 12, 2018 and is headquartered in Rockville, MD.

Breakthrough Diagnostics, Inc. engages in the development of blood tests for the early detection of neurodegenerative disorders. Its primary product is the Lympro Test, a blood screening diagnostic test for Alzheimer’s disease. The company is headquartered in New York, NY.

Theralink Technologies, Inc. engages in the provision of biomarker assay services in the areas of oncology. The firm offers personalized medicine data through TheraLink assays to assist the biopharmaceutical industry and clinical oncologists in identifying drug treatments. It develops phosphoproteomic technologies that measure the activation status of signaling pathways. The company was founded on October 16, 2008 and is headquartered in Golden, CO.